Error creating thumbnail: convert: unable to open image `/home/wikinvest/src_live_2/mediawiki/images/9/9f/Global_thinking.svg.png': No such file or directory @ blob.c/OpenBlob/2480. convert: unable to open file `/home/wikinvest/src_live_2/mediawiki/images/9/9f/Global_thinking.svg.png' @ png.c/ReadPNGImage/2889. convert: missing an image filename `/home/wikinvest/src_live_2/mediawiki/images/thumb/9/9f/Global_thinking.svg.png/30px-Global_thinking.svg.png' @ convert.c/ConvertImageCommand/2800.
|This article describes a concept which could impact a variety of companies, countries or industries. To see what companies and articles reference this concept page, click here.|
Asthma is a respiratory condition in which the airways become inflammed and constrict, usually in response to one or more environmental triggers. As a serious and potentially fatal condition if left untreated, asthma can be managed by avoiding triggers and with drug therapy.
Over 300 million people suffer from asthma, which translates to a drug market worth over $15 billion. While drugs to manage asthma have existed for several decades, pharmaceutical companies have developed faster acting and more effective products over the years. GlaxoSmithKline's Advair and AstraZeneca's Symbicort are the latest generation of asthma drugs, and are poised to take over the market as older products go generic.
According to a new report published by Transparency Market Research (http://www.transparencymarketresearch.com/asthma-and-copd-market.html) In the overall Asthma and COPD market, Advair remained the market leader with USD 7,802 million in 2011 and is expected to reach USD xxxx million in 2014. Singulair is the second largest drug in terms of revenue at UD 5479 million in 2011. The patent that provides U.S. market exclusivity for Singulair will expire in August 2012. It is expected that within 2-3 years following patent expiration, it will lose substantially all U.S. sales of Singulair, with most of those declines coming in the first full year following patent expiration.
The asthma market is currently $15 billion and is projected to reach $17 billion by 2010. The major players are:
Older single-therapy drugs include:
Health insurance companies such as Aetna (AET), UnitedHealth Group (UNH), WellPoint Health Networks (WLP), and AFLAC (AFL) may be hurt by the increased incidence of asthma because reimbursement costs will increase.
Asthma describes the narrowing of airways in the lungs. Environmental triggers vary from person to person, but can include smoke, exercise, cold air, and other allergens such as dust mites, pollen, and infections. Symptoms of asthma include breathlessness, coughing, and wheezing. Over 300 million people summer from asthma, which translates to a drug market worth over $15 billion.
Following the success of Advair and Symbicort, several new respiratory products are combination drugs. GSK and Novartis are developing new once-a-day combination products that are longer acting than drugs current on the market. The new drugs would be more convenient for patients because they only need to be taken once a day, rather than several times a day with current drugs.
Monoclonal antibodies are a new class of drugs that use antibodies to bind to asthma-inducing allergens, asthma-inducing antibodies, or components of the immune system that contribute to asthma pathogenesis. Novartis and Genentech's Xolair, which targets IgE antibodies, is currently the first and only monoclonal antibody on the market. It is used to treat severe asthma, which although representing only 0.5 percent of the market, has disproportionately high costs. 2007 sales of Xolair was $472 million. Other monoclonal antibodies in development target cytokines or cytokine receptors such as IL-4, IL-5, IL-9, and IL-13.
6. Asthma And COPD Drug Market http://www.transparencymarketresearch.com/asthma-and-copd-market.html